Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I—Comparison between Healthy Subjects and Patients with Hypertension

Biomarkers are increasingly used to provide decision making data early in phase I by showing Proof of Mechanism or Proof of Concept (PoM/PoC). For antihypertensive agents, the administration of multiple doses (md) to hypertensive patients is assumed to be necessary for an early go/no-go decision. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wensing, Georg, Ochmann, Klaus, Boettcher, Michael, Schäfer, Anja, Kuhlmann, Jochen
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2007
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717814/
https://www.ncbi.nlm.nih.gov/pubmed/19662194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717814/
https://www.ncbi.nlm.nih.gov/pubmed/19662194

Ejemplares similares